array(13) { ["code"]=> string(2) "en" ["id"]=> string(1) "1" ["native_name"]=> string(2) "US" ["major"]=> string(1) "1" ["active"]=> string(1) "1" ["default_locale"]=> string(2) "en" ["encode_url"]=> string(1) "0" ["tag"]=> string(2) "en" ["missing"]=> int(0) ["translated_name"]=> string(2) "US" ["url"]=> string(224) "https://www.prosigna.com/en/resource/analytical-validation-of-the-pam50-based-prosigna-breast-cancer-prognostic-gene-signature-assay-and-ncounter-analysis-system-using-formalin-fixed-paraffin-embedded-breast-tumor-specimens/" ["country_flag_url"]=> string(87) "https://www.prosigna.com/wp-content/plugins/sitepress-multilingual-cms/res/flags/en.png" ["language_code"]=> string(2) "en" } native: US
translated: US
IN the US OUTSIDE the US
CONTACT US
You are now entering a page intended for healthcare professionals only, if you are a patient or a member of the public, we will address you to a dedicated webpage.